One-year cost of HF substantial in the US

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.455, 2004-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A record price of $US20 000 has been revealed by manufacturing partners Roche and Trimeris for a one-year supply of their new drug enfuvirtide [`Fuzeon']

Inpharma, Vol. 1, Iss. 1380, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

A record price of $US20 000 has been revealed by manufacturing partners Roche and Trimeris for a one-year supply of their new drug enfuvirtide [`Fuzeon']

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 405, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Cost of OAB-related comorbidities substantial

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 479, 2005-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Substantial impact of US nonreimbursed care

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 440, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

VAP hospital costs substantial in the US

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 417, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite